Browsing by Author Martin, Miguel

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 14 of 14
Issue DateTitleAuthor(s)
2015-01A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
2018Biosimilars.Martin, Miguel
2015-05Defining breast cancer intrinsic subtypes by quantitative receptor expression.
2017-02-01Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.
2017Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions.
2016HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.
2017-10Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer.Echavarria, Isabel; Jerez, Yolanda; Martin, Miguel; López-Tarruella, Sara
2017-03-28Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.
2015-04-16Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy.
2018-04-15Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification.
2016-02Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.
2018Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy.
2015-05-01PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.
2018-11Simulation modeling approaches to answer clinically relevant questions in breast cancer low-risk populations.Calin, Ana; Martin, Miguel; Lopez-Tarruella, Sara